Drug intelligence / Profile preview

Tiaogan Jianpi Hexue

Development stage: Phase 4
Administration: Oral

Overview

Tiaogan Jianpi Hexue is a Traditional Chinese Medicine (TCM) formula. It has been evaluated in a randomized controlled clinical trial for its efficacy in combination with adefovir dipivoxil (ADV) for the treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B patients. The combination therapy demonstrated superior HBeAg loss compared to ADV monotherapy, suggesting an improved therapeutic effect and safety profile for this patient population.

Other names: 调肝健脾和血颗粒

Beyond the preview

Go deeper on Tiaogan Jianpi Hexue.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tiaogan Jianpi Hexue.